Daniel Drozd

Articles by Daniel Drozd

24 Real-world Use of Neratinib Post-Pertuzumab (P) and –Ado-Trastuzumab Emtansine (T-DM1)

ByKathryn Martin,Hope Rugo, MD,Gregory Vidal, MD, PhD,Nina Oestreicher,Deepa Lalla,Gillian Hanson,Daniel Drozd,Kristie Traverso,Dan DiPrimeo,Debu Tripathy, MD

April 18th 2022

Latest Updated Articles

24 Real-world Use of Neratinib Post-Pertuzumab (P) and –Ado-Trastuzumab Emtansine (T-DM1)
April 18th 2022

Trending on CancerNetwork

FDA Grants Fast Track Designation to ERAS-0015 for Pancreatic Adenocarcinoma

Botensilimab/Balstilimab Elicits Major Pathologic Responses in Colon Cancer

How Significant is the Approval of Daraxonrasib in Pancreatic Cancer?

FDA Approves Rusfertide in Polycythemia Vera

ADI-212 Receives FDA IND Clearance for Castration-Resistant Prostate Cancer